Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.

@article{Turpie2001PentasaccharideOC,
  title={Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.},
  author={Alexander G. G. Turpie},
  journal={American heart journal},
  year={2001},
  volume={142 2 Suppl},
  pages={S9-15}
}
BACKGROUND Patients undergoing orthopedic surgery are at particularly high risk for venous thromboembolism (VTE) and as such often receive prophylactic low-molecular-weight heparin (LMWH) or warfarin. However, efficacy and safety limitations of these agents have prompted a search for alternative antithrombotic drugs. METHODS A new pentasaccharide, Org31540/SR90107A, the first of a class of synthetic and highly selective Factor Xa inhibitors, was investigated in a phase II double-blind, dose… CONTINUE READING